Blood Screening Market Overview and Scope
The Blood Screening Market size was valued at USD 3.34 billion in 2024 and is expected to reach USD 8.16 billion by 2032, growing at a CAGR of 11.88% over the forecast period of 2025-2032.
The global blood screening market is growing rapidly due to the increase in the number of transfusion-transmissible infections (TTIs) such as HIV, Hepatitis B, Hepatitis C, and syphilis, and the need for blood donation screening. The demand for safe blood is on the rise, along with blood donations, and technological advances, including NAT and ELISA testing. Rising government regulations and healthcare initiatives to improve blood safety are also believed to fuel the market growth. Automation, digitalization, and the incorporation of state-of-the-art diagnostics are also improving the accuracy and efficacy of testing in blood banks and hospitals globally.
The U.S. blood screening market size was valued at USD 0.95 billion in 2024 and is expected to reach USD 2.24 billion by 2032, growing at a CAGR of 11.36% over the forecast period of 2025-2032.
The U.S. is the dominating country in the North American blood screening market due to the strong healthcare infrastructure, high investment in healthcare, mainly in blood services, and a high number of blood donors and increased cases of infections in the country. Such superiority is also enhanced by next-generation public–private partnerships, early adoption of new genomics testing and ELISA technology, and a favorable reimbursement environment that promotes the use of novel screening tools.
Blood Screening Market Dynamics
Drivers
- Increasing Incidence of Transfusion-Transmittable Infections (TTIs) to Drive the Market
Rising burden of TTIs such as HIV, Hepatitis B, Hepatitis C, and syphilis is significantly driving the traction of the blood screening market growth. Millions of individuals need blood transfusions every year to save lives, and the risk of transmitting these infections through the administration of insufficiently screened and unscreened blood products remains a significant public health threat. It has further raised the alert among medical practitioners and authorities about the need for complete testing. This is driving countries to enhance their blood safety procedures and impose higher testing standards to avoid disease transmission, thereby surging demand for sophisticated blood screening products.
The International Society of Blood Transfusion reported in 2024 that NAT detected >3,100 NAT-positive donations in 2019 alone, with >22,000 overall since NAT introduction—mostly being HBV— signaling the ongoing global burden of TTIs and the importance of continuing to employ sensitive screening techniques.
- Technological Advancements in Screening Techniques are Boosting Market Growth
The new screening technologies currently under development are further evolving testing speed, accuracy, and the ability to screen for infections earlier. Nucleic acid testing (NAT), for example, can detect pathogens during the window period before antibodies have been produced and therefore significantly enhances the safety of blood. Likewise, NGS and multiplex platforms allow identification of more than one infection from a single sample. Integrated software systems-driven automated platforms are helping to continue to make workflow processes in blood banks and hospitals more efficient as well. Such technological enhancements not only contribute to better performance of the tests but also promote the use of the test using shorter assay times and lower labour costs, and thus are well suited for high-throughput applications.
Automation and integrated platforms are proliferating through government–industry partnerships. For instance, in May 2024, New York Blood Center Enterprises and Thermo Fisher announced a high-throughput blood-genotyping array to enhance matching precision in transfusions.
Restraint
- The Expensive Advanced Screening Technologies are Limiting the Growth of the Market
The blood screening market trends are also restrained by the cost of integrating novel testing technologies, including nucleic acid testing (NAT), next-generation sequencing (NGS), and fully automated analyzers. Those systems come with a high upfront cost — not just for the machine, but also for the company’s proprietary reagents, routine service calls, and software updates.
More costly are infrastructure changes, such as temperature-controlled rooms and the ability to back up the power to manage testing 24 hours a day. At many particularly low- and middle-income blood banks, the annual fee is not feasible. However, the economic constraints associated with these technologies have restricted the use of high-throughput sensitive screening methodologies and resulted in the use of outdated low-sensitivity methods of screening for disease, such as rapid testing and manual ELISA, that compromise the overall quality and safety of the blood supply.
Blood Screening Market Segmentation Analysis
By Product & Service
The reagents & kits segment dominated the blood screening market share in 2024 with a 74.20%, as reagents and kits are crucial for routine and high-throughput testing activities. These are required to be used for the implementation of assays such as NAT, ELISA, rapid diagnostics, etc., that are used for screening the transfusion-transmissible infections, including HIV, Hepatitis B, and Hepatitis C. The repeat purchase nature of the consumables for every screening process results in the continuous demand from all blood banks and diagnostic laboratories. Moreover, the improvement of reagent formulation, enhancement of reliability, and the ready-to-use kits in the market are some of the major factors contributing to the rapid expansion of this segment, which is gaining pace in the global ARTs market.
The instruments segment is projected to grow at the highest CAGR during the forecast period, due to the growing automation and digitalization of blood screening processes. There is an increasing demand for high-throughput and fully automated analyzers, particularly in large blood banks and hospitals, where they can help increase efficiency, decrease manual mistakes, and shorten turnaround time. Multiplexing approaches and state-of-the-art detection technologies (e.g., chemiluminescence immunoassays, real-time PCR) also reinforce the trend towards more complex devices.
By Technology
The nucleic acid test segment of the blood screening market has the highest market share in 2024, with a 40.30%, as it has higher sensitivity and specificity to detect transfusion-transmissible infections (TTIs) such as HIV, Hepatitis B, and Hepatitis C at an early stage in 2024. NAT can detect viral RNA or DNA in the window of period during which the antibody is not detectable, which greatly diminishes the possibility of transmitting the infection through blood transfusion. Its wide acceptance in developed countries, due to strict regulatory concerns and to secure its blood supplies, means that NAT has become a gold standard in blood screening. Its short run time and ability to be interconnected with autoanalyzers also make it an efficient test in high-throughput settings.
The next-generation sequencing segment is expected to witness the fastest growth over the forecast period as it can offer complete and high-throughput blood sample analysis. NGS allows for the simultaneous identification of multiple pathogens and mutations, and genetic markers in a single test, rendering it of great interest for advanced blood safety applications and the identification of rare pathogens. With the cost of sequencing decreasing and bioinformatics tools becoming more widely available, NGS is emerging as a popular assay in both clinical and research applications. Furthermore, its application in personalized medicine and epidemiological monitoring makes NGS a revolutionary technology for the future of blood screening.
By End User
The blood banks segment held the largest share in the blood screening market in 2024, with a 78.69%. Blood banks are significant centers for the collection, processing, and storage of blood and blood components. These centers are obligated to ensure all donated blood is tested for a range of transfusion-transmissible diseases, including HIV, Hepatitis B, Hepatitis C, and syphilis. Blood banks process a high number of samples per day, so it is important to have a permanent use of high-sensitivity techniques such as NAT and ELISA. Moreover, many national government policies and mandates in all markets demand strict testing of blood banks before any transfusion, so the blood bank stands out as a key player in the market.
The hospitals segment is projected to grow at the highest CAGR during the forecast period, owing to the rising number of surgeries, trauma cases, and blood transfusion procedures. Since hospitals are interested in enhancing the safety of their patients and decreasing the risks of infection, many of them are initiating on-site blood screening, especially in the case of large and tertiary care institutions. Integration with automated systems and point-of-care diagnostics is also increasing accessibility and efficiency for blood screening in the hospital.
Blood Screening Market Regional Insights
North America dominated the blood screening market with a 37.43% market share in 2024, as it has developed a healthcare system, a strong blood donation culture, and favorable rules for TTIs from regulatory authorities. The growth of the market in this region is fuelled by the focus on early adoption of high-end screening technologies such as NAT and CLIA, especially in the U.S. and Canada. Furthermore, the key players being here, robust government support, and the volume of blood transfusions, have also propelled the region to lead the blood safety assurance.
The Asia Pacific region is experiencing the fastest growth with a 12.51% CAGR over the forecast period in the blood screening market analysis due to awareness about blood-borne diseases, the need for safe blood, and growing Healthcare facilities in developing nations. Public health programs are making progress on this new blood screening. China, India, and Japan are funding a lot for the blood screening. Government Acts and Policies are encouraging voluntary blood donations and the use of newer technologies for testing, such as ELISA and NAT. In addition, the increasing prevalence of infectious diseases and large patient base in the region have been boosting the demand for advanced, safe, and large-volume blood testing.
The blood screening market is growing rapidly in Europe due to strict regulatory policies, a rise in the number of surgeries, and increasing demand for safe blood transfusions. Various nations in the region have mandated the screening of infections such as HIV, Hepatitis B, and C, leading to increased penetration of advanced technologies such as NAT and next-generation sequencing. Moreover, the rising knowledge of transfusion safety, robust public health infrastructure, and constant advancements in diagnostic platforms are also driving the steady growth of the market in the region.
Latin America is witnessing the moderate growth of the blood screening market, due to increasing awareness about transfusion-transmissible infections and government efforts to facilitate voluntary blood donation. Countries are enhancing blood safety regulations, which in turn is leveling up the penetration of screening technologies such as ELISA and rapid tests. Limited availability of sophisticated diagnostic infrastructure in rural regions is still a problem.
The Middle East & Africa (MEA) region will witness a gradual growth owing to rising healthcare infrastructure, investment in public health programs, and rising requirements for safe blood due to the high prevalence of diseases. Aided by rollouts of diagnostic technology in various areas of the region, governments are prompting an increase in diagnostic capacity, although high costs of equipment and understaffed personnel are likely to temper the rate of market growth.
Key Companies in the Blood Screening Market
The blood screening market companies are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Grifols S.A., Siemens Healthineers AG, bioMérieux SA, Becton, Dickinson and Company (BD), DiaSorin S.p.A., and other players.
Recent Developments in the Blood Screening Industry
-
April 2024 – Abbott reported that its i-STAT TBI cartridge gained U.S. Food and Drug Administration (FDA) clearance for use with whole blood. This expansion enables clinicians to test patients with suspected traumatic brain injury (TBI) or concussion at the bedside and receive lab-quality results in 15 minutes. The test was previously cleared for plasma or serum, requiring processing in the laboratory and delaying diagnosis.
- May 2024 – Thermo Fisher Scientific launched a new array-based system for extended blood group research to further increase transfusion safety. This cutting-edge platform is aimed at enabling future innovations in blood compatibility testing and enhancing transfusion medicine outcomes.
Blood Screening Market Report Scope:
Report Attributes Details Market Size in 2024 USD 3.34 Billion Market Size by 2032 USD 8.16 Billion CAGR CAGR of 11.88% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Product & Service (Reagents & Kits, Instruments, Software & Services)
• By Technology (Nucleic Acid Test, ELISA, Rapid Tests, Western Blot Assays, Next-generation Sequencing)
• By End User (Blood Banks, Hospitals)Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles Abbott Laboratories, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Grifols S.A., Siemens Healthineers AG, bioMérieux SA, Becton, Dickinson and Company (BD), DiaSorin S.p.A., and other players.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Disease Incidence & Prevalence (2024)
5.2 Blood Donation and Collection Trends, by Region (2024)
5.3 Healthcare Infrastructure & Spending on Blood Safety (2024)
5.4 Technological Adoption in Screening Platforms (2024)
5.5 Regulatory and Policy Developments (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Blood Screening Market Segmentation By Product & Service
7.1 Chapter Overview
7.2 Reagents & Kits
7.2.1 Reagents & Kits Market Trends Analysis (2021-2032)
7.2.2 Reagents & Kits Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Instrument
7.3.1 Instrument Market Trends Analysis (2021-2032)
7.3.2 Instrument Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Software & Services
7.4.1 Software & Services Market Trends Analysis (2021-2032)
7.4.2 Software & Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Blood Screening Market Segmentation By Technology
8.1 Chapter Overview
8.2 Nucleic Acid Test
8.2.1 Nucleic Acid Test Market Trend Analysis (2021-2032)
8.2.2 Nucleic Acid Test Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 ELISA
8.3.1 ELISA Market Trends Analysis (2021-2032)
8.3.2 ELISA Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Western Blot Assays
8.4.1 Western Blot Assays Market Trends Analysis (2021-2032)
8.4.2 Western Blot Assays Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Next-generation Sequencing
8.5.1 Next-generation Sequencing Market Trends Analysis (2021-2032)
8.5.2 Next-generation Sequencing Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Rapid Tests
8.6.1 Rapid Tests Market Trends Analysis (2021-2032)
8.6.2 Rapid Tests Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Blood Screening Market Segmentation By End User
9.1 Chapter Overview
9.2 Blood Banks
9.2.1 Blood Banks Market Trends Analysis (2021-2032)
9.2.2 Blood Banks Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Hospitals
9.3.1 Hospitals Market Trends Analysis (2021-2032)
9.3.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Blood Screening Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.2.4 North America Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.5 North America Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.2.6.2 USA Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.6.3 USA Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.2.7.2 Canada Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.7.3 Canada Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.2.8.2 Mexico Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.2.8.3 Mexico Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Blood Screening Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.4 Europe Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.5 Europe Blood Screening Market Estimates and Forecasts, By End User(2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.1.6.2 Germany Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.1.6.3 Germany Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.7.2 France a Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.7.3 France Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.8.2 UK Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.8.3 UK Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.9.2 Italy Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.9.3 Italy Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.10.2 Spain Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.10.3 Spain Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Blood Screening Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.12.3 Poland Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.12.3 Poland Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.13.2 Turkey Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.13.3 Turkey Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Blood Screening Market Estimates and Forecasts, By End User(2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Blood Screening Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.6.2 China Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.6.3 China Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.7.2 India Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.7.3 India Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.8.2 Japan Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.8.3 Japan Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.9.2 South Korea Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.9.3 South Korea Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.10.2 Singapore Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.10.3 Singapore Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.11.2 Australia Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.11.3 Australia Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Blood Screening Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3Middle East and Africa Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.5.6.2 UAE Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.6.3 UAE Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.5.8.2 Qatar Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.8.3 Qatar Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.5.9 2 South Africa Blood Screening Market Estimates and Forecasts By Technology (2021-2032) (USD Billion)
10.5.9 3 South Africa Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Blood Screening Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.6.4 Latin America Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.5 Latin America Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.6.6.2 Brazil Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.6.3 Brazil Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.6.7.2 Argentina Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.7.3 Argentina Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Blood Screening Market Estimates and Forecasts, By Product & Service (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Blood Screening Market Estimates and Forecasts, By Technology (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Blood Screening Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Bio-Rad Laboratories Inc.,
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Thermo Fisher Scientific Inc.,
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Danaher Corporation (Beckman Coulter),
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Grifols S.A
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Siemens Healthineers AG
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 bioMérieux SA
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Becton
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Dickinson and Company (BD),
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysi
12. Use Cases and Best Practices
13. Conclusion
Key Market Segments:
By Product & Service
- Reagents & Kits
- Instrument
- Software & Services
By Technology
- Nucleic Acid Test
- ELISA
- Rapid Tests
- Western Blot Assays
- Next-generation Sequencing
By End User
- Blood Banks
- Hospitals
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Poland
- Turkey
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
